Abstract: SA-PO0106
Cystic Kidney Disease Mortality in the United States, 1999-2024: A Population-Level Analysis of CDC WONDER Data
Session Information
- ADPKD and Cystic Kidney Disease - 3
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Genetic Diseases of the Kidneys
- 1201 Genetic Diseases of the Kidneys: Cystic (Monogenic)
Authors
- Kodali, Naga Anvesh, University of Central Florida/HCA Florida Ocala Hospital, Ocala, Florida, United States
- Seth, Sukriti, University of Central Florida/HCA Florida Ocala Hospital, Ocala, Florida, United States
- Desai, Hardik, AB Plus Multispecialty Hospital, Ahmedabad, Gujarat, India
- Nwakoby, Izuchukwu E., University of Central Florida/HCA Florida Ocala Hospital, Ocala, Florida, United States
Background
Cystic kidney disease (CKD) spans congenital cystic dysplasias and inherited polycystic disorders, yet its long-term US mortality footprint has not been comprehensively quantified across a quarter-century. Contemporary trend data are essential for aligning surveillance, screening and therapeutic priorities.
Methods
CDC WONDER Multiple Cause of Death databases were interrogated for all decedents whose underlying cause was coded Q61.0–Q61.9 between 1999 and 2024. The 1999–2020 (bridged-race) and 2018–2024 (single-race) files were spliced at 2017/2018 after confirming identical national counts in overlap years. Annual deaths and age-adjusted mortality rates (AAMR; per 100,000; Year-2000 US Standard Population) were tabulated and stratified by sex, ten-year age band, US Census region, 2013 NCHS urbanization tier, race and Hispanic ethnicity. Annual percent change (APC) with 95% CIs was estimated by log-linear regression of ln (value) on calendar year.
Results
13,514 CKD attributable deaths were recorded across the 26-year window. Annual deaths rose from 418 (1999) to 625 (2024), an APC of +1.55% (95% CI 1.20–1.91; p<0.001); AAMR climbed in parallel (APC +2.08%; 95% CI 0.35–3.85; p=0.021). Infants <1 year formed the largest age stratum (4,085; 31.0%), reflecting the congenital nature of many Q61 entities. Males exceeded females (M:F 1.14; APC +1.93% vs +1.14%). The South carried the greatest absolute burden (5,000 deaths) and the steepest APC (+2.16%; 95% CI 1.67–2.65). A clear urban–rural gradient was evident, large central metros accounting for 28.6% of deaths.
Conclusion
US Cystic Kidney Disease mortality has risen steadily and significantly across 1999–2024, with disproportionate impact on infants, males and the southern region. These findings justify more granular subcode and rate-based analyses to separate congenital pediatric mortality from adult inherited cystic kidney disease and argue for strengthened prenatal counselling, equitable nephrology access in underserved regions and prioritized research into disease-modifying therapy.